Cargando…

Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience

Objective: In this study, we aimed to compare [68Ga]FAPI PET/CT and [18F]FDG PET/CT imaging to detect lesions in multiple myeloma. Methods: A total of 14 patients with multiple myeloma who underwent [68Ga]FAPI PET/CT and [18F]FDG PET/CT imaging were included in this retrospective study. SUV(max) val...

Descripción completa

Detalles Bibliográficos
Autores principales: Elboga, Umut, Sahin, Ertan, Cayirli, Yusuf Burak, Okuyan, Merve, Aktas, Gokmen, Haydaroglu Sahin, Handan, Dogan, Ilkay, Kus, Tulay, Akkurd, Dervis Murat, Cimen, Ufuk, Mumcu, Vuslat, Kilbas, Benan, Celen, Yusuf Zeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875266/
https://www.ncbi.nlm.nih.gov/pubmed/35202189
http://dx.doi.org/10.3390/tomography8010024
_version_ 1784657877245362176
author Elboga, Umut
Sahin, Ertan
Cayirli, Yusuf Burak
Okuyan, Merve
Aktas, Gokmen
Haydaroglu Sahin, Handan
Dogan, Ilkay
Kus, Tulay
Akkurd, Dervis Murat
Cimen, Ufuk
Mumcu, Vuslat
Kilbas, Benan
Celen, Yusuf Zeki
author_facet Elboga, Umut
Sahin, Ertan
Cayirli, Yusuf Burak
Okuyan, Merve
Aktas, Gokmen
Haydaroglu Sahin, Handan
Dogan, Ilkay
Kus, Tulay
Akkurd, Dervis Murat
Cimen, Ufuk
Mumcu, Vuslat
Kilbas, Benan
Celen, Yusuf Zeki
author_sort Elboga, Umut
collection PubMed
description Objective: In this study, we aimed to compare [68Ga]FAPI PET/CT and [18F]FDG PET/CT imaging to detect lesions in multiple myeloma. Methods: A total of 14 patients with multiple myeloma who underwent [68Ga]FAPI PET/CT and [18F]FDG PET/CT imaging were included in this retrospective study. SUV(max) values of [68Ga]FAPI and [18F]FDG were compared according to lesion locations. Also, lesion localization ability of both imaging methods was compared on the patient basis. Results: In 4 of 14 patients, [68Ga]FAPI PET/CT and [18F]FDG PET/CT have not detected any bone lesions. In 8 of the remaining 10 patients [18F]FDG PET/CT detected bone lesions but in this group, 6 patients showed more higher SUV(max) values than [18F]FDG PET/CT in [68Ga]FAPI PET/CT.In contrast, 2 of 8 patients showed more higher SUV(max) values than [68Ga]FAPI PET/CT in [18F]FDG PET/CT. Moreover, [68Ga]FAPI PET/CT detected bone lesions in two patients, which werenot detected by [18F]FDG PET/CT. Also, in five patients, [68Ga]FAPI PET/CT showed more bone lesions in comparison with[18F]FDG PET/CT. Only one patient, [18F]FDG PET/CT showed more bone lesions. Three extramedullary involvements were observed in the following locations: lung, presacral lymph node, and soft tissue mass lateral to the right maxillary sinus. Among these involvements, higher SUV(max) values were observed in the lung and presacral lymph node with [68Ga]FAPI compared to [18F]FDG. However, the soft tissue mass showed a higher SUV(max) value in [18F]FDG than [68Ga]FAPI. Conclusions: No significant superiority was observed in [68Ga]FAPI PET/CT over [18F]FDG PET/CT in patients with MM. However, [68Ga]FAPI PET/CT can be utilized as a complementary imaging method to [18F]FDG PET/CT in some settings, especially in low-[18F]FDG affinity and inconclusive cases. Considering the favorable aspects of [68Ga]FAPI PET/CT in MM, such as low background activity, absence of non-specific bone marrow, and physiological brain involvement, further studies with a larger sample size should be conducted.
format Online
Article
Text
id pubmed-8875266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88752662022-02-26 Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience Elboga, Umut Sahin, Ertan Cayirli, Yusuf Burak Okuyan, Merve Aktas, Gokmen Haydaroglu Sahin, Handan Dogan, Ilkay Kus, Tulay Akkurd, Dervis Murat Cimen, Ufuk Mumcu, Vuslat Kilbas, Benan Celen, Yusuf Zeki Tomography Article Objective: In this study, we aimed to compare [68Ga]FAPI PET/CT and [18F]FDG PET/CT imaging to detect lesions in multiple myeloma. Methods: A total of 14 patients with multiple myeloma who underwent [68Ga]FAPI PET/CT and [18F]FDG PET/CT imaging were included in this retrospective study. SUV(max) values of [68Ga]FAPI and [18F]FDG were compared according to lesion locations. Also, lesion localization ability of both imaging methods was compared on the patient basis. Results: In 4 of 14 patients, [68Ga]FAPI PET/CT and [18F]FDG PET/CT have not detected any bone lesions. In 8 of the remaining 10 patients [18F]FDG PET/CT detected bone lesions but in this group, 6 patients showed more higher SUV(max) values than [18F]FDG PET/CT in [68Ga]FAPI PET/CT.In contrast, 2 of 8 patients showed more higher SUV(max) values than [68Ga]FAPI PET/CT in [18F]FDG PET/CT. Moreover, [68Ga]FAPI PET/CT detected bone lesions in two patients, which werenot detected by [18F]FDG PET/CT. Also, in five patients, [68Ga]FAPI PET/CT showed more bone lesions in comparison with[18F]FDG PET/CT. Only one patient, [18F]FDG PET/CT showed more bone lesions. Three extramedullary involvements were observed in the following locations: lung, presacral lymph node, and soft tissue mass lateral to the right maxillary sinus. Among these involvements, higher SUV(max) values were observed in the lung and presacral lymph node with [68Ga]FAPI compared to [18F]FDG. However, the soft tissue mass showed a higher SUV(max) value in [18F]FDG than [68Ga]FAPI. Conclusions: No significant superiority was observed in [68Ga]FAPI PET/CT over [18F]FDG PET/CT in patients with MM. However, [68Ga]FAPI PET/CT can be utilized as a complementary imaging method to [18F]FDG PET/CT in some settings, especially in low-[18F]FDG affinity and inconclusive cases. Considering the favorable aspects of [68Ga]FAPI PET/CT in MM, such as low background activity, absence of non-specific bone marrow, and physiological brain involvement, further studies with a larger sample size should be conducted. MDPI 2022-02-01 /pmc/articles/PMC8875266/ /pubmed/35202189 http://dx.doi.org/10.3390/tomography8010024 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Elboga, Umut
Sahin, Ertan
Cayirli, Yusuf Burak
Okuyan, Merve
Aktas, Gokmen
Haydaroglu Sahin, Handan
Dogan, Ilkay
Kus, Tulay
Akkurd, Dervis Murat
Cimen, Ufuk
Mumcu, Vuslat
Kilbas, Benan
Celen, Yusuf Zeki
Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience
title Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience
title_full Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience
title_fullStr Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience
title_full_unstemmed Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience
title_short Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience
title_sort comparison of [68ga]-fapi pet/ct and [18f]-fdg pet/ct in multiple myeloma: clinical experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875266/
https://www.ncbi.nlm.nih.gov/pubmed/35202189
http://dx.doi.org/10.3390/tomography8010024
work_keys_str_mv AT elbogaumut comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience
AT sahinertan comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience
AT cayirliyusufburak comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience
AT okuyanmerve comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience
AT aktasgokmen comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience
AT haydaroglusahinhandan comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience
AT doganilkay comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience
AT kustulay comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience
AT akkurddervismurat comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience
AT cimenufuk comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience
AT mumcuvuslat comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience
AT kilbasbenan comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience
AT celenyusufzeki comparisonof68gafapipetctand18ffdgpetctinmultiplemyelomaclinicalexperience